Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024

Aim. To evaluate the effect of the use of the double antiplatelet therapy (DAT) with ticagrelor compared to DAT with clopidogrel and antithrombotic therapy with acetyl salicylic acid (ASA) in patients with acute coronary syndrome and patients with high coronary risk on the target indicator (CP) of the state program (GP) “Development of Healthcare” and the federal project “Fight against cardiovascular diseases” — reducing mortality from diseases of the circulatory system (BSC).

Material and methods. All adult Russian patients with a diagnosis of ACS eligible for DAT were considered as the target population; in the second and third years, only patients with high coronary risk continued treatment. The calculation of the number of deaths that can be prevented using DAT ticagrelor 90 mg + ASA vs DAT of clopidogrel + ASA within 1st year from the date of diagnosis was based on the clinical efficacy data of the PLATO study. The number of deaths that can be prevented with the use of DAT ticagrelor 60 mg + ASA — instead of ASA monotherapy patients with a history of myocardial infarction was made based in the clinical efficacy results of the PEGASUS study. It was calculated what proportion of the target indicators could be achieved in 2022-24 years by using DAT with ticagrelor instead of clopidogrel or ASA monotherapy.

Results. The use of DAT with ticagrelor vs DAT with clopidogrel or ASA for the treatment of patients with ACS will prevent additional 5389, 5704 and 6012 deaths in 2022-2024, that will ensure the implementation of the CP “reduction of mortality from BSC” GP “Development of healthcare” in the Russian Federation by 36,9%, 26,0% and 20,6% respectively.

Conclusion. The use of DAT with ticagrelor for the treatment of patients with acute coronary syndrome ensure the implementation of the CP “reduction of mortality from BSC” GP “Development of healthcare” in the Russian Federation in 2024 by 20,6%.

1. Federal state statistics service. (In Russ.) https://rosstat.gov.ru/folder/12781. (дата обращения: 01.11.2021).

2. Mortality from diseases of the circulatory system (per 100 thousand population). Unified interdepartmental information and statistical system. (In Russ.) https://fedstat.ru/indicator/55382.

3. Data from the Central research Institute for health organization and Informatization of the Ministry of health of the Russian Federation. (In Russ.) https://box.almazovcentre.ru/index.php/s/EYpf3hPX5OrViHq?fbclid=IwAR3jBOaHp-tf3P13ztI7uUBAhjo1Jem6MYsFZ9RubSQbegl1wgrqp5uDVfs.

4. Resolution of the Government of the Russian Federation of 26.12.2017 N 1640 (ed. of 24.07.2021) “On approval of the state program of the Russian Federation “Development of healthcare”. (In Russ.)

5. Passport of the Federal project “Fight against cardiovascular diseases”. (In Russ.) https://www.rosminzdrav.ru/poleznye-resursy/natsproektzdravoohranenie/bssz.

6. Resolution of the Government of the Russian Federation of 11.12.2020 No. 2081 “On Amendments to the State Program of the Russian Federation “Development of healthcare” and the Recognition of Certain Acts of the Government of the Russian Federation as Invalid”. (In Russ.) http://publication.pravo.gov.ru/Document/View/0001202012150049?rangeSize=1.

7. Resolution of the Government of the Russian Federation No. 1254 of July 24, 2021 “On Amendments to Appendix No. 10 to the State Program of the Russian Federation “Development of Healthcare”. (In Russ.) http://publication.pravo.gov.ru/Document/View/0001202108020037.

8. Order of the Ministry of Health of the Russian Federation dated 09/24/2021 N 936n “On approval of the list of medicines for medical use to provide outpatient care for persons who have suffered acute cerebral circulatory disorders, myocardial infarction, and who have undergone coronary artery bypass grafting, angioplasty with stenting and catheter ablation for cardiovascular diseases”. (In Russ.) http://publication.pravo.gov.ru/Document/View/0001202110150031.

9. Russian Society of Cardiology. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. (In Russ.) doi:10.15829/29/1560-4071-2020-4103.

10. Barbarash OL, Duplyakov DV, Zateischikov DA, et al. 020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russian Journal of Cardiology. 2021;26(4):4449. (In Russ.) doi:10.15829/1560-4071-2021-4449.

11. Zhuravleva MV, Zyryanov SK, Paleev FN, et al. Effects of ticagrelor in patients with acute coronary syndrome on the targets of the national cardiovascular program. Russian Journal of Cardiology. 2020;25(5):3931. (In Russ.) doi:10.15829/1560-4071-2020-3931.

12. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Russian Journal of Cardiology. 2018;(8):113-63. (In Russ.) doi:10.15829/1560-4071-2018-8-113-163.

13. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. doi:10.1056/NEJMoa0904327.

14. The Ministry of health of the Russian Federation, the Department of monitoring, analysis and strategic development of health “Central scientific-research Institute of organization and Informatization of health” Ministry of health of Russia. Morbidity of the adult population of Russia in 2019 with a diagnosis established for the first time in life. Statistical data. part III. Moscow 2020. (In Russ.)

15. doi:10.1136/openhrt-2016-000580.

16. Instructions for medical use of the drug Brilinta. (In Russ.) http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8fcdf646-b3fe-4532-b0fe-3f5c64b247c9&t=.

17. Bonaca MP, Storey RF, Theroux P, et al. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol. 2017;70(11):1368-75. doi:10.1016/j.jacc.2017.07.768.

18. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics. 2007;25(1):3-6. doi:10.2165/00019053-200725010-00002.